Chugai and Gero Join Forces to Develop Innovative Therapies for Age-Related Diseases

Chugai and Gero Signed a License and Joint Research Agreement

Image Credits: BioPharma BoardRoom

Announcement

Chugia Pharmaceutical Co., Ltd. and Gero PTE.LTD both a Singapore-based biotechnology company, has signed a licensed and joint research agreement to develop and introduce therapies for age diseases. The collaboration between these two companies will fuel the skin health market. This collaboration will fuel research and development and will lead to expansion, elevating the introduction of new therapies in the respective regions and the healthcare market. The joint efforts will stimulate the patient outcome and enable access to alternative therapy options. It's a contribution to healthcare professionals to accelerate their study and understanding, and to adopt this treatment in suitable respective healthcare sector. The innovative approach to this development is a positive change to the global market.

Agreement

Under this agreement, Chugai will hire antibody drug candidates via its antibody engineering technologies for Gero’s new drug. The drug was discovered through the analysis of human datasets, which have been collected through its unique AI discovery platform. Gero will ensure that Chugai gets exclusive rights to commercialize, create, manufacture, develop, and research antibodies for the addressed targets. Regarding an upfront payment, Chugai will pay 250 million USD total only if sales and development show profit and certain achievements. If Chugai officially launches its product, then the company will also pay royalties on sales to Gero.

Views and Statements

President and CEO of Chugai, Dr. Osamu Okuda, said, “The Company believes that an open innovation with external partners, involving global players, is essential for the class drug discovery achievement that will bolster the growth strategy for 2030. By integrating Gero’s discovery technology with Chugai’s drug discovery technologies, together we will leverage the innovation.”

CEO of Gero, Peter Fedichev, said, “Our company’s AI platform is available to address therapeutic targets that serve various age-related diseases and focuses on the potential of mainly covering the aging concept. With this partnership, we are focusing on translating the current insights in therapeutics, which will support the restoration of lost or failed functions. This agreement is a step towards accomplishing Gero’s mission to cover the biological process of human aging.”

CBO of Gero, Alex Kadet, said, “We are happy to partner with Chugai, a popular pharmaceutical company that covers the bridge between a therapeutic designed technology platform and human data-driven discovery. Together, we will develop an excellent therapy that will meet the needs of various patients with age-related diseases.”